AKArunava Kali

Arunava Kali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arunava Kali has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Srirangaraj Sreenivasan

    Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed University), Puducherry, India

    6 shared publications
  • Sreenivasan Srirangaraj

    Dept. of Microbiology Mahatma Gandhi Medical College & Research Institute Sri Balaji Vidyapeeth University Pondicherry India

    5 shared publications
  • M. V. Pravin Charles

    Department of Microbiology, MGMCRI, Sri Balaji Vidyapeeth Deemed-to-be-University, Puducherry, India

    4 shared publications
  • Sivaraman Umadevi

    Professor, Department of Microbiology, Mahatma Gandhi Medical College & Research Institute , Pondicherry, India

    4 shared publications
  • Joshy M Easow

    Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth Deemed-to-be-University, Puducherry, India

    2 shared publications
  • Joshy Maducolil Easow

    Department of Microbiology, Mahatma Gandhi Medical College and Research Institute (MGMCRI) Sri Balaji Vidyapeeth (Deemed to be University) Puducherry India

    2 shared publications

Latest Publications

  • Open Access

    Drug Approvals in India-2023–2025: Trends and Insights

    by Arunava Kali, Kartik Janardan Salwe, Ashish Suresh

    Analysis of drug approvals by the Central Drugs Standard Control Organization (CDSCO) between 2023 and 2025 reveals evolving regulatory priorities that increasingly emphasize innovation, precision medicine, and alignment with global drug development trends. Among the 67 drugs approved, anticancer agents constituted the largest therapeutic class, followed by antimicrobials, immunomodulators/targeted immune therapies, gastrointestinal drugs, and neuropsychiatric agents. Most CDSCO-approved drugs already had Food and Drug Administration approval. Comparison with India’s mortality and disability-adjusted life year data shows partial alignment with India’s growing noncommunicable disease burden, particularly cancers, diabetes, cardiovascular disease, and neuropsychiatric conditions. However, chronic respiratory diseases, tuberculosis, diarrheal illnesses, and perinatal infections were underrepresented, indicating a relative gap in unmet needs. Notably, approvals for rare and genetic disorders increased, indicating expanding regulatory attention to orphan diseases.

  • Open Access

    Breakpoint to Minimum Inhibitory Concentration Quotient: A Critical Metric for Optimizing Antimicrobial Decision-making

    by Arunava Kali, Valentina Yogamoorthi, M. V. Pravin Charles

    Antibiotic selection and dosing strategies are fundamentally guided by antibiotic susceptibility, which relies on minimum inhibitory concentration (MIC) values and established clinical breakpoints. Breakpoint to MIC quotient (BMQ) is the ratio of the clinical breakpoint to the MIC of the infecting pathogen and serves as a determinant of the drug’s efficacy margin. A higher BMQ suggests a greater likelihood of treatment success, whereas a lower quotient may indicate borderline efficacy, requiring dose optimization or alternative therapy. This quotient aids in balancing drug selection when various agents exhibit identical susceptibility categorizations but differ in clinical susceptibility breakpoint. BMQ has emerged as a critical parameter in optimizing antimicrobial therapy by integrating pharmacokinetic/pharmacodynamic relationships with bacterial susceptibility profiles. This narrative review aims to explore the concept, significance, challenges, and future prospects of BMQ in guiding antimicrobial therapy.

  • Open Access

    MIC breakpoints of XDR Enterobacterales Towards Polymyxin B, Colistin, and Tigecycline - Clinical Insights and Therapeutic Outcomes from A Descriptive Study

    by R. Kalaivani, Arunava Kali, Joshy M. Easow

    The prevalence of antibiotic resistance among Gram-negative bacteria, particularly Enterobacterales, is rising. Extensively drug-resistant (XDR) Enterobacterales demonstrate nonsusceptibility to all except two or fewer classes of antibiotics, where it retains susceptibility to at least one agent. Besides tigecycline, colistin and polymyxin B are often the only available therapeutic options in developing countries. The aim of this study was to determine the susceptibility of XDR Enterobacterales to colistin, polymyxin B, and tigecycline by determining the MIC using microbroth dilution and analyzing the treatment outcome. A descriptive study was done at Mahatma Gandhi Medical College and Research Institute, Pondicherry, from May 2023 to July 2023. The study included non-ICU patients aged 18 years or older, who had infections caused by XDR Enterobacterales isolated from clinical specimens during the study period and provided informed consent. All quantitative measurement values in this study were analyzed using descriptive statistical methods. Colistin and polymyxin B MIC of 109 clinical isolates of XDR Enterobacterales were tested by microbroth dilution. Tigecycline MIC was determined for 73 of these isolates. Forty-eight patients received colistin or polymyxin B monotherapy and their treatment outcomes were documented. Out of the 109 XDR isolates, 16 (14.7%) were resistant to colistin, while 11 (10.1%) were resistant to polymyxin B. Tigecycline MIC values ranged from 0.06 µg/mL to 4 µg/mL. Successful treatment outcome was observed in 23.5% of patients with colistin and/or polymyxin B resistant isolates, whereas it was 70.9% in patients with colistin and polymyxin B intermediate isolates. The present study revealed that K. pneumoniae emerged as the predominant isolate among XDR Enterobacterales in our healthcare facility. Although only a small proportion of strains exhibited resistance to polymyxin B, colistin, and tigecycline, the treatment outcomes were notably poor in the case of colistin and/or polymyxin B resistant strains, underscoring the grave therapeutic limitations posed by these resistant pathogens.

  • Open Access

    CLINICAL AND MICROBIOLOGICAL PROFILE OF SECONDARY BLOODSTREAM INFECTIONS RESULTING FROM URINARY TRACT INFECTION CAUSED BY ENTEROBACTERALES

    by Nandhini S, Arunava Kali, Valentina Y, Pravin Charles M.V, Joshy M Easow

    Objectives: Bloodstream infection (BSI) is a common sequelae of urinary tract infections (UTIs) and it requires early detection and appropriate antibiotic therapy. This study analyzed the clinical and microbiological profile of secondary BSI resulting from UTI caused by Enterobacterales. Methods: In this retrospective study, National Healthcare Safety Network criteria were used to define the cases of UTI and secondary BSI attributed to UTI. Data from medical records and laboratory reports of patients from January to May 2024 were compiled and analyzed. Results: Among 932 urine samples with significant growth of Enterobacterales, 48 were blood cultures positive. Out of them, 26 patients (11 males and 15 females) met the criteria of BSI secondary to UTI as the same isolates also grew in blood specimens which was taken within the secondary BSI attribution period. Nine patients had catheter-associated symptomatic UTI (CA-SUTI) while 14 were non-CA-SUTI and 3 had asymptomatic bacteriuria. In urine culture, Escherichia coli (n=22, 68.1% multi-drug resistant and 31.8% non-multi-drug resistant [MDR]), Klebsiella pneumoniae (n=3, all MDR), and Citrobacter koseri (n=1, non-MDR) strains were isolated. Diabetes, renal calculi, fever, Foley’s catheter, age >60 years, intensive care unit admission, and hospital stay >10 days were more among individuals with MDR infections. Cefoperazone-sulbactam, piperacillin/tazobactam, and nitrofurantoin had good outcomes. Conclusion: Cefoperazone-sulbactam, piperacillin/tazobactam, and nitrofurantoin were effective for treating patients with BSI attributed to UTI in our hospital with good outcomes. Hence, these antibiotics might have a critical role as empirical therapy for such, particularly those with underlying health conditions and risk factors for MDR infections.

  • Open Access

    Curcumin as a Promising Therapy for COVID-19: A Review

    by Arunava Kali, M. V. Pravin Charles

    The ongoing COVID-19 pandemic has spurred intense research efforts to identify effective therapeutic options. Among the potential candidates, curcumin, a naturally occurring polyphenol obtained from turmeric, has gained considerable attention due to its diverse pharmacological properties. This review examines the existing literature on curcumin’s potential as a new promising treatment for COVID-19. Curcumin demonstrates antiviral effects by modulating key signaling pathways for entry and multiplication of SARS-CoV-2 in host cells. It limits viral entry in host cells as it binds and inhibits S-protein, TMPRSS2, and ADAM17 enzymes required for cytoadherence and membrane fusion. It also downregulates SARS-CoV-2 replication by preventing the release of the viral genomic RNA into the cytoplasm from virus-containing vacuoles and subsequently inhibits enzymes required for viral replication. Rennin–angiotensin–aldosterone system (RAS) dysfunction, especially increased angiotensin-converting enzyme (ACE)-Angiotensin II-AT1R axis activity, is associated with prothrombotic state, acute respiratory distress syndrome, and lung injury in COVID-19 patients. Curcumin increases soluble ACE2 cellular ACE2 activity, restores RAS normal function, and mitigates these complications. Curcumin also exerts anti-inflammatory and immunomodulatory actions. It reduces the secretion of pro-inflammatory cytokines through inhibition of toll-like receptors (TLRs), namely, TLR2, TLR4, and TLR9, and enhances the production of anti-inflammatory cytokines like interleukin-10. In addition, it prevents the progression of tissue damage and inflammation by reactive oxygen species (ROS) through ROS scavenging enzymes. Due to its antiviral, anti-inflammatory, antioxidant, and immunomodulatory properties, curcumin has emerged as an attractive candidate for combating various aspects of COVID-19 pathogenesis, such as excessive inflammation, oxidative stress, viral multiplication, and immune dysregulation. However, limited clinical evidence is currently available to support its efficacy, specifically against COVID-19. Thus, further research, including clinical trials, is warranted to evaluate curcumin’s therapeutic potential and determine its optimal dosage, formulation, and safety for COVID-19 patients. Overall, based on its favorable pharmacological properties and promising preclinical data, curcumin holds promise as a treatment for COVID-19, but its clinical utility requires further exploration.


  • Gut-Lung Axis-A Compass to Navigate Microbiome Landscape in COVID-19

    by Arunava Kali, Pravin Charles

    Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.

  • Open Access

    Unveiling the Eris Subvariant: The Next Challenge in the COVID-19 Pandemic?

    by Arunava Kali

    Since the COVID-19 pandemic's onset, the SARS-CoV-2 virus has displayed remarkable mutation abilities, resulting in distinct variants. Alpha, Beta, Gamma, Delta, and Omicron are major World Health Organization (WHO)-identified variants of concern. The Omicron variant and its sub-lineages dominated globally in 2022. A novel strain, EG.5.1 (Eris), originating from Omicron's XBB sub-lineage, has recently sparked a significant COVID-19 surge across continents. Detected since June 2023, EG.5.1 is linked to increased cases in Europe, the Americas, and Asia. Factors like waning immunity, overcrowding, and poor air quality contributed to its rise. This variant is likely to prevail over other circulating variants and become dominant in UK by September 2023. Surveillance of its global epidemiology and implementing preventive measures have become imperative in light of the current situation. None. Received: 07 August 2023 Accepted: 12 August 2023 Article published online: 08 September 2023 © 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India


  • Open Access

    Pefloxacin susceptibility as a surrogate test to detect ciprofloxacin-resistance in typhoidal Salmonella

    by Arunava Kali, Pravin M. V Charles, Sreenivasan Srirangaraj, K S Seetha

    Pefloxacin susceptibility as a surrogate test to detect ciprofloxacin-resistance in typhoidal Salmonella-IJMR-Print ISSN No:-2394-546X Online ISSN No:-2394-5478Article DOI No:-10.18231/j.ijmr.2019.044,Indian Journal of Microbiology Research-IP Innovative Publication Pvt Limited, Medical Journals Publication, Open Ac